Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG ...

The FDA has approved updated COVID vaccines for adults over age 65 and younger people with chronic conditions.

The FDA has approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech and Novavax-Sanofi for the 2026-27 season.

Four COVID ​shots have been approved for use ⁠in the U.S. These are Moderna's mNEXSPIKE and Spikevax, Pfizer-BioNTech's ...

Novavax's (NVAX) partners received approvals for the XFG-adapted Nuvaxovid COVID-19 vaccine in the US, European Union and Japan for the 2026-2027 vaccination season, the company s ...

The U.S. Food and Drug Administration has approved on Thursday updated COVID-19 vaccines from Moderna Inc. MRNA, Pfizer Inc.

Shares of Novavax Inc NVAX are trading higher Tuesday morning as buying interest continues across late-stage vaccine ...

Novavax benefited from this deal, but moving forward, there is far too much uncertainty surrounding it. For one, demand for coronavirus vaccines might no longer be what it once was. That's on top of ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...

Novavax, Inc.'s valuation remains too high given its reliance on one-off revenues, uncertain royalties, and a complex Sanofi partnership. The company's Q1 2025 earnings were boosted by non-recurring ...

Pfizer and BioNTech's XFG-adapted COMIRNATY has also received U.S. FDA approval for the 2026-2027 season. COMIRNATY XFG is approved for adults aged 65 years and older and individuals aged 5 through 64 ...